Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Apoorva, Sunit Kumar Singh
The emergence of highly zoonotic viral infections has propelled bat research forward. The viral outbreaks including Hendra virus, Nipah virus, Marburg virus, Ebola virus, Rabies virus, Middle East respiratory syndrome coronavirus, SARS-CoV and the latest SARS-CoV-2 have been epidemiologically linked to various bat species. Bats possess unique immunological characteristics that allow them to serve as a potential viral reservoir. Bats are also known to protect themselves against viruses and maintain their immunity...
April 22, 2024: Future Microbiology
#2
REVIEW
Xinyu Qiu, Feng Wang, Ailong Sha
Henipavirus (HNV) is well known for two zoonotic viruses in the genus, Hendra virus (HeV) and Nipah virus (NiV), which pose serious threat to human and animal health. In August 2022, a third zoonotic virus in the genus Henipavirus, Langya virus (LayV), was discovered in China. The emergence of HeV, NiV, and LayV highlights the persistent threat of HNV to human and animal health. In addition to the above three HNVs, new species within this genus are still being discovered. Although they have not yet caused a pandemic in humans or livestock, they still have the risk of spillover as a potential threat to the health of humans and animals...
April 17, 2024: Comparative Immunology, Microbiology and Infectious Diseases
#3
JOURNAL ARTICLE
Muskan Gupta, Tuhin Mukherjee, Satyajit Mohanty
No abstract text is available yet for this article.
April 17, 2024: Infectious Disorders Drug Targets
#4
JOURNAL ARTICLE
Chunmei Cui, Pengfei Hao, Chaozhi Jin, Wang Xu, Yuchen Liu, Letian Li, Shouwen Du, Limin Shang, Xin Jin, Ningyi Jin, Jian Wang, Chang Li
Nipah virus (NiV) is a highly lethal zoonotic virus with a potential large-scale outbreak, which poses a great threat to world health and security. In order to explore more potential factors associated with NiV, a proximity labeling method was applied to investigate the F, G, and host protein interactions systematically. We screened 1996 and 1524 high-confidence host proteins that interacted with the NiV fusion (F) glycoprotein and attachment (G) glycoprotein in HEK293T cells by proximity labeling technology, and 863 of them interacted with both F and G...
April 8, 2024: International Journal of Molecular Sciences
#5
JOURNAL ARTICLE
Neelam Suman, Ekta Khandelwal, Pavankumar Chiluvuri, Diptesh S Rami, Shivakshi Chansoria, Aldrin Jerry, Rahul Tiwari
OBJECTIVE: This study assessed Nipah virus (NiV) encephalitis epidemiology, clinical outcomes, and risk variables to inform treatment and prevention. METHODOLOGY: In a PubMed systematic search, 929 citations were found. After screening and eligibility, 22 studies were included. This study obtained age, gender, geographic regions, diagnostic methods, data collection methods, and bias risk. The case fatality rate (CFR) and NiV infection risk variables were evaluated by meta-analysis...
February 2024: Journal of Pharmacy & Bioallied Sciences
#6
JOURNAL ARTICLE
Zhaoqian Wang, Matthew McCallum, Lianying Yan, Cecily A Gibson, William Sharkey, Young-Jun Park, Ha V Dang, Moushimi Amaya, Ashley Person, Christopher C Broder, David Veesler
Langya virus (LayV) is a recently discovered henipavirus (HNV), isolated from febrile patients in China. HNV entry into host cells is mediated by the attachment (G) and fusion (F) glycoproteins which are the main targets of neutralizing antibodies. We show here that the LayV F and G glycoproteins promote membrane fusion with human, mouse, and hamster target cells using a different, yet unknown, receptor than Nipah virus (NiV) and Hendra virus (HeV) and that NiV- and HeV-elicited monoclonal and polyclonal antibodies do not cross-react with LayV F and G...
April 16, 2024: Proceedings of the National Academy of Sciences of the United States of America
#7
EDITORIAL
Komal, Diksha, Niraj S Patil, Amandeep Singh
No abstract text is available yet for this article.
April 8, 2024: Infectious Disorders Drug Targets
#8
JOURNAL ARTICLE
Li Chen, Mengmeng Sun, Huajun Zhang, Xinghai Zhang, Yanfeng Yao, Ming Li, Kangyin Li, Pengfei Fan, Haiwei Zhang, Ye Qin, Zhe Zhang, Entao Li, Zhen Chen, Wuxiang Guan, Shanshan Li, Changming Yu, Kaiming Zhang, Rui Gong, Sandra Chiu
Nipah virus (NiV) is a World Health Organization priority pathogen and there are currently no approved drugs for clinical immunotherapy. Through the use of a naïve human phage-displayed Fab library, two neutralizing antibodies (NiV41 and NiV42) targeting the NiV receptor binding protein (RBP) were identified. Following affinity maturation, antibodies derived from NiV41 display cross-reactivity against both NiV and Hendra virus (HeV), whereas the antibody based on NiV42 is only specific to NiV. Results of immunogenetic analysis reveal a correlation between the maturation of antibodies and their antiviral activity...
April 6, 2024: Nature Communications
#9
JOURNAL ARTICLE
Larry Zeitlin, Robert W Cross, Courtney Woolsey, Brandyn R West, Viktoriya Borisevich, Krystle N Agans, Abhishek N Prasad, Daniel J Deer, Lauren Stuart, Maria McCavitt-Malvido, Do H Kim, James Pettitt, James E Crowe, Kevin J Whaley, David Veesler, Antony Dimitrov, Dafna M Abelson, Thomas W Geisbert, Christopher C Broder
No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra virus (HeV) G glycoprotein, m102.4, has been tested in a phase 1 trial and has been provided under compassionate use for both HeV and NiV exposures. NiV is a highly pathogenic zoonotic paramyxovirus causing regular outbreaks in humans and animals in South and Southeast Asia. The mortality rate of NiV infection in humans ranges from 40% to more than 90%, making it a substantial public health concern...
April 3, 2024: Science Translational Medicine
#10
E Clancey, S L Nuismer, S N Seifert
UNLABELLED: Zoonotic pathogens pose a significant risk to human health, with spillover into human populations contributing to chronic disease, sporadic epidemics, and occasional pandemics. Despite the widely recognized burden of zoonotic spillover, our ability to identify which animal populations serve as primary reservoirs for these pathogens remains incomplete. This challenge is compounded when prevalence reaches detectable levels only at specific times of year. In these cases, statistical models designed to predict the timing of peak prevalence could guide field sampling for active infections...
March 20, 2024: bioRxiv
#11
JOURNAL ARTICLE
Nadim Sharif, Nazmul Sharif, Afsana Khan, Shuvra K Dey
No abstract text is available yet for this article.
April 2024: Health Science Reports
#12
JOURNAL ARTICLE
Prakasini Satapathy, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Sarvesh Rustagi, Neelima Kukreti, Rachana Mehta, Ranjit Sah
No abstract text is available yet for this article.
March 29, 2024: Infectious Diseases
#13
JOURNAL ARTICLE
Anoop Kumar As, Rima R Sahay, Chandni Radhakrishnan, Shihabudheen P, Sathishkumar Kandath, Deepak Y Patil, Anita M Shete, Shamsudheen M, Gayathri Ramakrishnan, Anitha Puduvail Moorkoth, Nivedita Gupta, Pragya D Yadav, Sheela Godbole, Lathika Velichapat Ramakrishnan, Shameer Vadekkandiyil, Danish Ekkalayil, Nithasha V, Anukumar Balakrishnan, Niyas K Pullor, Neelakandhan Asokan, Reena Kalathil Joseph, Priyanka R Nair, Sreejayan Meethale Purayil, Thomas Mathew, Rajaram Kizhakkekandiyil, Jayesh Kumar Poovullathil, Kannan Sabarinath Ps, Ullas Pt, Kalpana George, Asma Rahim, Surendra Kumar, Siba S, Sreelekshmy Mohandas, Lekshmi S Rajan, Shamin Punnath Ramachandran, Seethu Ponnu Thampi, Ashadevi, Thekkumkara Surendran Anish, Priya Chandran, Anuja Mohan, Bindu Vadakkayil, Shaji Cheriya Koroth, Nimin Hafeez, Rajasi Ranjini Sasi, Minu Abraham
India experienced its sixth Nipah virus (NiV) outbreak in September 2023 in the Kozhikode district of Kerala state. The NiV is primarily transmitted by spillover events from infected bats followed by human-to-human transmission. The clinical specimens were screened using real-time RT-PCR, and positive specimens were further characterized using next-generation sequencing. We describe here an in-depth clinical presentation and management of NiV-confirmed cases and outbreak containment activities. The current outbreak reported a total of six cases with two deaths, with a case fatality ratio of 33...
March 2024: Journal of Medical Virology
#14
JOURNAL ARTICLE
Olalekan John Okesanya, Kingsley Chukwuka Agbo, Safayet Jamil, Don Eliseo Lucero-Prisno Iii
No abstract text is available yet for this article.
April 2024: New Microbes and New Infections
#15
JOURNAL ARTICLE
R Balasubramanian, Sreelekshmy Mohandas, Ullas P Thankappan, Anita Shete, Dilip Patil, Kannan Sabarinath, Basavaraj Mathapati, Rima Sahay, Deepak Patil, Pragya D Yadav
INTRODUCTION: Since 2018, the Indian state of Kerala has reported four Nipah virus (NiV) disease outbreaks, raising concerns about NiV spillover from bats to the human population. Considering this, a cross-sectional study was undertaken in the Pteropus medius bat population around the Nipah virus-affected regions of Kozhikode, Kerala, India, during February, July, and September 2023. METHODS: Throat swabs, rectal swabs, and organ samples were collected from bats to test for NiV using the real-time reverse transcriptase polymerase chain reaction (RT-PCR), while serum samples were screened for anti-Nipah IgG antibodies through ELISA...
2024: Frontiers in Microbiology
#16
JOURNAL ARTICLE
Xi Yang, Kexin Xu, Siying Li, Jiangnian Zhang, Yinli Xie, Yongliang Lou, Xingxing Xiao
Nipah virus (NiV), a bat-borne zoonotic viral pathogen with high infectivity and lethality to humans, has caused severe outbreaks in several countries of Asia during the past two decades. Because of the worldwide distribution of the NiV natural reservoir, fruit bats, and lack of effective treatments or vaccines for NiV, routine surveillance and early detection are the key measures for containing NiV outbreaks and reducing its influence. In this study, we developed two rapid, sensitive and easy-to-conduct methods, RAA-CRISPR/Cas12a-FQ and RAA-CRISPR/Cas12a-FB, for NiV detection based on a recombinase-aided amplification (RAA) assay and a CRISPR/Cas12a system by utilizing dual-labeled fluorophore-quencher or fluorophore-biotin ssDNA probes...
March 18, 2024: Analyst
#17
JOURNAL ARTICLE
Yadira Pastor, Olivier Reynard, Mathieu Iampietro, Mathieu Surenaud, Florence Picard, Nora El Jahrani, Cécile Lefebvre, Adele Hammoudi, Léa Dupaty, Élise Brisebard, Stéphanie Reynard, Élodie Moureaux, Marie Moroso, Stéphanie Durand, Claudia Gonzalez, Lucia Amurri, Anne-Sophie Gallouët, Romain Marlin, Sylvain Baize, Eve Chevillard, Hervé Raoul, Hakim Hocini, Mireille Centlivre, Rodolphe Thiébaut, Branka Horvat, Véronique Godot, Yves Lévy, Sylvain Cardinaud
Nipah virus (NiV) has been recently ranked by the World Health Organization as being among the top eight emerging pathogens likely to cause major epidemics, whereas no therapeutics or vaccines have yet been approved. We report a method to deliver immunogenic epitopes from NiV through the targeting of the CD40 receptor of antigen-presenting cells by fusing a selected humanized anti-CD40 monoclonal antibody to the Nipah glycoprotein with conserved NiV fusion and nucleocapsid peptides. In the African green monkey model, CD40...
March 7, 2024: Cell reports medicine
#18
Evan A Eskew, Kevin J Olival, Jonna A K Mazet, Peter Daszak
Understanding viral infection dynamics in wildlife hosts can help forecast zoonotic pathogen spillover and human disease risk. Bats are particularly important reservoirs of zoonotic viruses, including some of major public health concern such as Nipah virus, Hendra virus, and SARS-related coronaviruses. Previous work has suggested that metapopulation dynamics, seasonal reproductive patterns, and other bat life history characteristics might explain temporal variation in spillover of bat-associated viruses into people...
February 26, 2024: bioRxiv
#19
JOURNAL ARTICLE
Kasopefoluwa Y Oguntuyo, Griffin D Haas, Kristopher D Azarm, Christian S Stevens, Luca Brambilla, Shreyas S Kowdle, Victoria A Avanzato, Rhys Pryce, Alexander N Freiberg, Thomas A Bowden, Benhur Lee
UNLABELLED: Nipah virus (NiV) is a highly lethal, zoonotic Henipavirus (HNV) that causes respiratory and neurological signs and symptoms in humans. Similar to other paramyxoviruses, HNVs mediate entry into host cells through the concerted actions of two surface glycoproteins: a receptor-binding protein (RBP) that mediates attachment and a fusion glycoprotein (F) that triggers fusion in an RBP-dependent manner. NiV uses ephrin-B2 (EFNB2) and ephrin-B3 (EFNB3) as entry receptors. Ghana virus (GhV), a novel HNV identified in a Ghanaian bat, uses EFNB2 but not EFNB3...
March 19, 2024: Journal of Virology
#20
REVIEW
Valerie Rodrigue, Katie Gravagna, Jacqueline Yao, Vaidehi Nafade, Nicole E Basta
OBJECTIVES: Nipah and Hendra are deadly zoonotic diseases with pandemic potential. To date, no human vaccine or monoclonal antibody (mAb) has been licensed to prevent disease caused by these pathogens. The aim of this scoping review was to identify and describe all Phase I, II, and III clinical trials of vaccine candidates or mAbs candidates designed to prevent Nipah and Hendra in humans and to compare the characteristics of the vaccine candidates to characteristics outlined in the Target Product Profile drafted by the World Health Organisation as part of the WHO Research & Development Blueprint for Action to Prevent Epidemics...
February 28, 2024: Tropical Medicine & International Health
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
